Berinert 2000 IU injektiokuiva-aine ja liuotin, liuosta varten Suomi - suomi - Fimea (Suomen lääkevirasto)

berinert 2000 iu injektiokuiva-aine ja liuotin, liuosta varten

csl behring gmbh - c1-esteraasin estäjä - injektiokuiva-aine ja liuotin, liuosta varten - 2000 iu - proteiini-c1-estäjät

Berinert 3000 IU injektiokuiva-aine ja liuotin, liuosta varten Suomi - suomi - Fimea (Suomen lääkevirasto)

berinert 3000 iu injektiokuiva-aine ja liuotin, liuosta varten

csl behring gmbh - c1-esteraasin estäjä - injektiokuiva-aine ja liuotin, liuosta varten - 3000 iu - proteiini-c1-estäjät

Zeposia Euroopan unioni - suomi - EMA (European Medicines Agency)

zeposia

bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosuppressantit - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Nexpovio Euroopan unioni - suomi - EMA (European Medicines Agency)

nexpovio

stemline therapeutics b.v. - selinexor - multiple myeloma - antineoplastiset aineet - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Byooviz Euroopan unioni - suomi - EMA (European Medicines Agency)

byooviz

samsung bioepis nl b.v. - ranibitsumabi - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - silmätautien - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Camcevi Euroopan unioni - suomi - EMA (European Medicines Agency)

camcevi

accord healthcare s.l.u. - leuprorelin mesilate - prostatiset kasvaimet - endokriinihoito - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Ximluci Euroopan unioni - suomi - EMA (European Medicines Agency)

ximluci

stada arzneimittel ag - ranibitsumabi - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - silmätautien - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ranivisio Euroopan unioni - suomi - EMA (European Medicines Agency)

ranivisio

midas pharma gmbh - ranibitsumabi - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - silmätautien - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Marzine 50 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

marzine 50 mg tabletti

viatris oy - cyclizine hydrochloride - tabletti - 50 mg - syklitsiini

Xylocain 2 % geeli Suomi - suomi - Fimea (Suomen lääkevirasto)

xylocain 2 % geeli

aspen pharma trading limited - lidocaine hydrochloride monohydrate - geeli - 2 % - lidokaiini